Selective Targeting of Cancer-Associated Fibroblasts by Engineered H-Ferritin Nanocages Loaded with Navitoclax

Galacto‐conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity

(2020) Estela González‐Gualda et al.   AGING CELL

Development of Tumor-Targeted Indocyanine Green-Loaded Ferritin Nanoparticles for Intraoperative Detection of Cancers

(2020) Leopoldo Sitia et al.   ACS Omega

Cancer-associated fibroblasts mediate cancer progression and remodel the tumouroid stroma

(2020) Judith Pape et al.   BRITISH JOURNAL OF CANCER

Multi-Omics Investigation of Innate Navitoclax Resistance in Triple-Negative Breast Cancer Cells

(2020) Michal Marczyk et al.   Cancers

Cancer-Associated Fibroblasts: Epigenetic Regulation and Therapeutic Intervention in Breast Cancer

(2020) Yeuan Ting Lee et al.   Cancers

Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management

(2020) Lavinia Salama et al.   Biomedicines

Nano-Strategies to Target Breast Cancer-Associated Fibroblasts: Rearranging the Tumor Microenvironment to Achieve Antitumor Efficacy

(2019) Marta Truffi et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy

(2019) Tongyan Liu et al.   Journal of Hematology & Oncology

Everolimus Nanoformulation in Biological Nanoparticles Increases Drug Responsiveness in Resistant and Low-Responsive Breast Cancer Cell Lines

(2019) Arianna Bonizzi et al.   Pharmaceutics

Targeting of the Cancer-Associated Fibroblast—T-Cell Axis in Solid Malignancies

(2019) Tom J. Harryvan et al.   Journal of Clinical Medicine

A peek into cancer-associated fibroblasts: origins, functions and translational impact

(2018) Valerie S. LeBleu et al.   Disease Models & Mechanisms

Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn’s Disease Strictures Ex Vivo

(2018) Marta Truffi et al.   INFLAMMATORY BOWEL DISEASES

Remodeling the Tumor Microenvironment with Emerging Nanotherapeutics

(2018) Qin Chen et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Turning foes to friends: targeting cancer-associated fibroblasts

(2018) Xueman Chen et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis

(2017) David Lagares et al.   Science Translational Medicine

H-Ferritin-nanocaged olaparib: a promising choice for both BRCA-mutated and sporadic triple negative breast cancer

(2017) S. Mazzucchelli et al.   Scientific Reports

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

(2016) Kristopher A. Sarosiek et al.   FEBS Journal

Ferritin nanocages: A biological platform for drug delivery, imaging and theranostics in cancer

(2016) Marta Truffi et al.   PHARMACOLOGICAL RESEARCH

Nanometronomic treatment of 4T1 breast cancer with nanocaged doxorubicin prevents drug resistance and circumvents cardiotoxicity

(2016) Serena Mazzucchelli et al.   Oncotarget

Cancer-associated fibroblasts: A multifaceted driver of breast cancer progression

(2015) Haojun Luo et al.   CANCER LETTERS

Tumor microenvironment: Sanctuary of the devil

(2015) Lanlan Hui et al.   CANCER LETTERS

The role of apoptosis in megakaryocytes and platelets

(2014) Benjamin T. Kile   BRITISH JOURNAL OF HAEMATOLOGY

Antibody–drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin

(2013) Elisabetta Falvo et al.   Nanoscale

Human ferritin for tumor detection and therapy

(2013) Kelong Fan et al.   Wiley Interdisciplinary Reviews-Nanomedicine and Nanobiotechnology

Therapeutic Effects of Deleting Cancer-Associated Fibroblasts in Cholangiocarcinoma

(2012) J. C. Mertens et al.   CANCER RESEARCH

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

(2012) C. M. Rudin et al.   CLINICAL CANCER RESEARCH

Phase I Study of Navitoclax (ABT-263), a Novel Bcl-2 Family Inhibitor, in Patients With Small-Cell Lung Cancer and Other Solid Tumors

(2011) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance

(2010) K. J. Campbell et al.   BLOOD

Identification of Expression Signatures Predictive of Sensitivity to the Bcl-2 Family Member Inhibitor ABT-263 in Small Cell Lung Carcinoma and Leukemia/Lymphoma Cell Lines

(2010) S. K. Tahir et al.   MOLECULAR CANCER THERAPEUTICS

The landscape of somatic copy-number alteration across human cancers

(2010) Rameen Beroukhim et al.   NATURE

Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein- 

(2010) M. Kraman et al.   SCIENCE

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

(2008) C. Tse et al.   CANCER RESEARCH

HPLC–MS/MS determination of a hardly soluble drug in human urine through drug–albumin binding assisted dissolution

(2008) Ramona Rodila et al.   JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES